Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2003
06/19/2003US20030114444 Analgesics
06/19/2003US20030114441 Heterocyclic anti-epileptogenic agents and methods of use thereof
06/19/2003US20030114439 Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
06/19/2003US20030114427 Remedies and/or preventives for nervous system disorders
06/19/2003US20030114425 Tiamenidine
06/19/2003US20030114424 Treatment of cerebrovascular disease
06/19/2003US20030114422 Thrombosis, brain disorders, cardiovascular disorders, Alzheimer's disease, Huntington diseases
06/19/2003US20030114420 Anticancer agents, autoimmunine diseases, congestive heart failure, skin disorders, antiinflammatory agents
06/19/2003US20030114418 Analgesics; antiinflammatory and arthritic agents; osteoarthritis; rheumatic diseases; gastrointestinal, nervous system, respiratory disorders; wound healing agents; vision defects; kits
06/19/2003US20030114416 Analgesics; antiinflammatory, -arthritic agents; vision defects; gastrointestinal and uorgenital disorders; wound healing agents; kits
06/19/2003US20030114387 Gamma secretase inhibitors
06/19/2003US20030114380 Amino acid sequence has 87-99 peptide residues
06/19/2003US20030114365 Neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins; treating neurodegenrative disorders
06/19/2003US20030114360 Peptide of lysine and tyrosine; viricides; treating neurodegenerative disorders
06/19/2003US20030113873 Screening modulators of G-protein coupled binding proteins; analgesics; muscle-relaxants; cognition activators; learning enhancement
06/19/2003US20030113869 Human FGF gene and gene expression products
06/19/2003US20030113844 Delayed rectifier potassium channel subunit
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113808 Apolipoprotein biopolymer markers predictive of alzheimers disease
06/19/2003US20030113803 Orphan receptor
06/19/2003US20030113789 Protease peptides; anticarcinogenic agents; neurotransmitters; antidiabetic agents
06/19/2003US20030113752 Detecting demyelinating nervous system disorder by measurement of stem cell factor (SCF)-apoptosis-response gene protein(SARG-1-) protein; antiproliferative agents; microtubule associated protein 1(map1a); cancer screening
06/19/2003US20030113707 Erythrocyte transport protein suspension obtained by removing fibrin and separating erythrocytes from hematocrit; storage stability; antihypoxic agents
06/19/2003US20030113393 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/19/2003US20030113380 Microparticles comprising polymeric binder and injection vehicle, wherein microparticles are suspended in vehicle at concentration of greater than 30 mg/ml to form suspension having viscosity of 600 cp at 20 degrees C
06/19/2003US20030113373 Delivery of multiple doses of medications
06/19/2003US20030113366 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/19/2003US20030113348 Non-laboratory strain used in the manufacture of a medicament for the oncolytic treatment of cancer; anticancer agents
06/19/2003US20030113321 Novel G-protein-coupled receptor protein and its DNA
06/19/2003US20030113309 Administering to a patient a compound for increasing neuronal metabolism of histamine to a histamine H2 agonist, to stimulate production of adenosine 3*,5*- cyclic phosphate at a level which maintains myelin against self degeneration
06/19/2003US20030113278 Treatment of excessive radiation (e.g. sunburn) exposure
06/19/2003US20030113269 Medical combinations comprising tiotropium and fluticasone proprionate
06/19/2003CA2655959A1 Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
06/19/2003CA2470111A1 Production of chirally pure .alpha.-amino acids and n-sulfonyl .alpha.-amino acids
06/19/2003CA2469893A1 Phenylalkynes
06/19/2003CA2469889A1 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
06/19/2003CA2469858A1 Functionalized higher diamondoids
06/19/2003CA2469709A1 Substituted hydrazones as inhibitors of cyclooxygenase-2
06/19/2003CA2469622A1 Substituted hydroxyethylamines
06/19/2003CA2469616A1 Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
06/19/2003CA2469613A1 Process for affecting neurologic progression
06/19/2003CA2469596A1 Ureas of 2-aminobenzothiazoles as adenosine modulators
06/19/2003CA2469588A1 Highly concentrated stable meloxicam solutions for needleless injection
06/19/2003CA2469340A1 Treating muscle wasting with selective androgen receptor modulators
06/19/2003CA2469316A1 Pyrimidine-based compounds useful as gsk-3 inhibitors
06/19/2003CA2469306A1 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/19/2003CA2469143A1 The use of acyl salicylates as heat shock inducers
06/19/2003CA2469049A1 Endogenous retrovirus polypeptides linked to oncogenic transformation
06/19/2003CA2468892A1 Vitamin d analogues
06/19/2003CA2468785A1 Beverage treated with nicotine
06/19/2003CA2468659A1 Urea substituted imidazopyridines
06/19/2003CA2468544A1 Vanilloid receptor ligands
06/19/2003CA2468202A1 Assays and implements for determining and modulating hsp90 binding activity
06/19/2003CA2468174A1 Amide substituted imidazopyridines
06/19/2003CA2468164A1 Sulfonamido substituted imidazopyridines
06/19/2003CA2467914A1 Prion inhibiting peptides and derivatives thereof
06/19/2003CA2467802A1 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
06/19/2003CA2467689A1 Stabilization of hypoxia inducible factor (hif) alpha using inhibitors of hif prolyl hydroxylase
06/19/2003CA2467614A1 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
06/19/2003CA2467593A1 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/19/2003CA2465759A1 Method for administering birb 796 bs
06/18/2003EP1319709A1 Disruption of the glutathione S-transferase-omega-1 gene
06/18/2003EP1319663A1 Antidepressant folic -, folinic- and glutamic-acid lithium salts
06/18/2003EP1319401A1 Compositions for regulating desire for smoking
06/18/2003EP1319182A2 G-csf analog compositions and methods
06/18/2003EP1319070A2 Mammalian receptor genes and uses
06/18/2003EP1319064A2 Gsk3 polypeptides
06/18/2003EP1319015A2 Olfactory and pheromones g-protein coupled receptors
06/18/2003EP1319008A2 Water soluble rapamycin esters
06/18/2003EP1319007A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
06/18/2003EP1319005A2 Substituted azepino[4,5-b]indoline derivatives
06/18/2003EP1319004A2 Substituted azepino[4,5-b]indole derivatives
06/18/2003EP1319001A1 Pyrazolopyridines and pyrazolopyridazines as antidiabetics
06/18/2003EP1318997A1 Pyrazole compounds useful as protein kinase inhibitors
06/18/2003EP1318996A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
06/18/2003EP1318994A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
06/18/2003EP1318993A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
06/18/2003EP1318992A1 Imidazole derivatives as raf kinase inhibitors
06/18/2003EP1318991A1 Benzoic acid derivatives and uses thereof
06/18/2003EP1318988A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
06/18/2003EP1318983A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
06/18/2003EP1318978A2 N-acylsulfonamide apoptosis promoters
06/18/2003EP1318977A1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof
06/18/2003EP1318838A1 Use of a nucleic acid/pei complex
06/18/2003EP1318836A2 Treatment of hyperproliferative diseases
06/18/2003EP1318828A1 Orally administered peptides to ameliorate atherosclerosis
06/18/2003EP1318825A2 Plant extract
06/18/2003EP1318820A2 Xenon as medicament
06/18/2003EP1318815A2 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches
06/18/2003EP1318814A2 Triazole compounds useful as protein kinase inhibitors
06/18/2003EP1318813A1 Stable pergolide mesylate and process for making same
06/18/2003EP1318805A2 Pharmaceutical composition containing citalopram
06/18/2003EP1318802A2 Substituted hydrazine derivatives
06/18/2003EP1318798A1 Water-soluble prodrugs of propofol for treatment of migraine
06/18/2003EP1318785A2 Pulmonary delivery in treating disorders of the central nervous system
06/18/2003EP1171128B1 Combination of n-butyldeoxynojirimycin (nb-dnj) and glycolipid degrading enzymes in therapy
06/18/2003EP1075475B1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production
06/18/2003EP1015451B1 Tetrahydro gamma-carbolines
06/18/2003EP1011709A4 Inhibition of apoptotis using prosaposin receptor agonists
06/18/2003EP0757677B1 Benzocyclohexylimidazolethione derivatives
1 ... 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 ... 1833